Research programme: antibody therapeutics - GlaxoSmithKline/Genentech
Alternative Names: Antibody therapeutics research programme - GlaxoSmithKline/GenentechLatest Information Update: 25 May 2007
Price :
$50 *
At a glance
- Originator Genentech; GlaxoSmithKline
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 08 Feb 2005 Early research in Undefined in USA (unspecified route)